



IMEXPHARM CORPORATION

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 03./2024/TTr-HĐQT-IMP

Cao Lanh City, April 5, 2024

PROPOSAL

Re.: On approval of the audited 2023 Financial Statements

Kindly Attn: Esteemed Shareholders of Imexpharm Corporation

- Pursuant to the Law on Enterprises;
- Pursuant to the Charter of Imexpharm Corporation (the "Company");
- Based on the audit report prepared by PwC (Vietnam) Limited dated March 26, 2024.

The Board of Directors ("BOD") respectfully submits to the 2024 Annual General Meeting of Shareholders ("AGM") for approval of the 2023 financial statements of Imexpharm Corporation which has been audited by PwC (Vietnam) Limited as follows:

The audited 2023 financial statements have been disclosed in accordance with regulations on the Company's website, including:

1. Company's profile;
2. Statement of the Board of Management;
3. Independent Auditor's Report;
4. Balance sheet (Form No. B01-DN);
5. Income Statement (Form No. B02-DN);
6. Cash Flow Statement (Form No. B03-DN);
7. Notes to the Financial Statements (Form No. B09-DN).

In which:

Some basic indicators in the audited 2023 financial statements:

No.	Major indicators	Unit	2023	2022
1	Total assets	VND	2,392,615,157,119	2,276,943,567,575
2	Gross revenue	VND	2,113,869,795,523	1,676,311,518,466
3	Net revenue	VND	1,994,036,910,377	1,643,706,514,646
4	Profit before tax	VND	377,272,934,101	291,404,142,440
5	Profit after tax	VND	299,556,005,542	223,540,317,602

Respectfully submitting to the AGM for consideration and approval.

ON BEHALF OF THE BOARD OF DIRECTORS
Chairwoman



CHUN CHAERHAN

